false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Glomeru ...
Membranous Nephropathy: Novel Target Antigen Disco ...
Membranous Nephropathy: Novel Target Antigen Discovery and Therapeutic Implications
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Laith Alrabadi reviewed advances in membranous nephropathy, focusing on antigen discovery and its potential to support precision medicine. The disease is characterized by subepithelial immune-complex deposits, and identification of antigens such as PLA2R and THSD7A has enabled noninvasive diagnosis and monitoring. Antibody levels can reflect immunologic activity, often changing before proteinuria improves or worsens.<br /><br />Newer antigens may point to underlying causes or associated conditions. For example, NELL1 is linked to malignancy and, in some settings, mercury-containing traditional medicines; other antigens have associations with syphilis, medications, neurologic disease, or transplantation. Antigen testing may therefore guide targeted investigations and, where possible, removal of a trigger.<br /><br />Treatment decisions should integrate proteinuria, antibody titers, kidney function, and biopsy findings. Lower-risk patients may be monitored for spontaneous remission, while higher-risk disease may warrant rituximab or cyclophosphamide. Because proteinuria can lag behind immunologic improvement, persistent proteinuria alone does not always justify more immunosuppression. Emerging approaches include obinutuzumab, plasma-cell therapies, and complement inhibition, though further evidence is needed. The talk concluded that antigen discovery has advanced care, but important questions about disease mechanisms and individualized treatment remain.
Asset Caption
Laith Al-Rabadi, MD
Meta Tag
Speaker
Laith Al-Rabadi
Keywords
membranous nephropathy
antigen discovery
PLA2R
THSD7A
NELL1
precision medicine
rituximab
×
Please select your language
1
English